A couple in their fifties preparing a protein-rich meal of salmon and salad together in a bright modern kitchen

Weight-Loss Medications Explained: GLP-1s, Safety, and Who Benefits

Important: This article is general education, not medical advice. Weight-loss medicines must be prescribed and monitored by a qualified clinician.

Weight-loss medicines such as Wegovy and Mounjaro are genuinely effective for the right person, but they are prescription treatments with real trade-offs, not shortcuts. This guide explains how they work, who they suit, what can go wrong, and how to make any weight you lose stay lost.

Why weight loss is so hard, and where medicines fit

Losing weight is hard because your body fights back. When you eat less, appetite hormones rise, fullness hormones fall, and your metabolism slows slightly. For many people, diet and exercise alone cannot overcome that pushback for long.

That is where anti-obesity medicines (often just called weight-loss drugs) come in. The newest group, the GLP-1 drugs, has changed the conversation almost overnight. Since late 2025, they are even available as daily pills, not just weekly injections.

But three questions matter more than the headlines: How do they work? Are they safe? And who is most likely to benefit? This article walks through each one so you can have a better-informed conversation with your doctor or pharmacist.

BMI basics: the numbers doctors look at

Most licences allow weight-loss medicine at a BMI of 30 or more, or 27 or more with a weight-related health problem. Body mass index (BMI) is your weight in kilograms divided by your height in metres squared.

BMI (kg/m²) Category Medication usually considered?
Under 25 Healthy weight No
25–29.9 Overweight Only if 27+ with a weight-related condition
30–34.9 Obesity (class 1) Yes, by licence
35–39.9 Obesity (class 2) Yes; NHS access often starts here
40+ Obesity (class 3) Yes; first priority for NHS Mounjaro

Weight-related conditions that count include type 2 diabetes, high blood pressure, abnormal cholesterol, sleep apnoea and heart disease.

Lower thresholds for some groups. UK guidance lowers cut-offs by 2.5 points for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, who face higher health risk at a lower BMI (NICE TA1026).

NHS access is stricter than the licence. In England, Mounjaro is being rolled out in phases. It started in 2025 with people with a BMI of 40+ and at least four qualifying conditions; from June 2026 this widened to a BMI of 35–39.9 plus four conditions (NHS South West London). Many people therefore pay privately.

BMI is a blunt tool. It ignores muscle and where fat sits, so doctors also look at waist size, blood tests and overall health.

The three major classes of anti-obesity drugs

Weight-loss medicines fall into three broad groups, and the newest group, incretin-based drugs such as Wegovy and Mounjaro, produces roughly two to four times the weight loss of the older options.

1. Incretin-based drugs (GLP-1 and GLP-1/GIP). These copy gut hormones that tell your brain you are full. Examples: semaglutide (Wegovy injection and pill), tirzepatide (Mounjaro, called Zepbound in the US), liraglutide (Saxenda) and, in the US, the orforglipron pill (Foundayo).

2. Brain-acting appetite drugs. These work on brain chemicals that control hunger and cravings. Examples: naltrexone-bupropion (Mysimba) and, mainly in the US, phentermine and phentermine-topiramate (Qsymia).

3. Fat-absorption blockers. Orlistat (Xenical, or lower-dose Alli over the counter) stops about a third of the fat you eat from being absorbed.

Medicine Class How taken Typical average weight loss in trials
Tirzepatide (Mounjaro / Zepbound) GLP-1 + GIP Weekly injection About 20%
Semaglutide 2.4 mg (Wegovy) GLP-1 Weekly injection About 14–15%
Oral semaglutide 25 mg (Wegovy pill) GLP-1 Daily pill, empty stomach About 14–17%
Orforglipron (Foundayo, US) GLP-1 Daily pill, any time About 11%
Liraglutide (Saxenda) GLP-1 Daily injection About 5–8%
Phentermine-topiramate (Qsymia, US) Brain-acting Daily capsule About 8–10%
Naltrexone-bupropion (Mysimba) Brain-acting Tablets twice daily About 5–6%
Orlistat (Xenical / Alli) Fat blocker With each meal About 3–5%

Figures for the newer drugs come from their main trials. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% average weight loss versus 13.7% for injectable semaglutide over 72 weeks (Drug Topics). The Wegovy pill gave 13.6% average loss including people who stopped, or 16.6% for those who stayed on it (Derm Digest). Orforglipron gave 11.1% versus 2.1% on placebo (Consultant360). Older-drug figures are approximate.

Is one worth discussing with your doctor? If your BMI meets the thresholds above and lifestyle changes have stalled, yes. The best choice depends on your other health conditions, cost, how you feel about injections, and what your health system will fund.

How GLP-1 drugs work in your body

GLP-1 drugs copy a hormone your gut releases after a meal, but they last for days instead of minutes, so the “I’ve had enough” signal stays switched on. GLP-1 (glucagon-like peptide-1) acts in several places at once:

  • Brain: it quietens hunger and “food noise”, so you think about food less and feel satisfied with smaller portions.
  • Stomach: it slows emptying, so you feel full sooner and stay full longer.
  • Pancreas: it releases insulin only when blood sugar is high, which lowers blood sugar with little risk of hypos on its own.
  • Liver: it reduces the sugar the liver pumps out between meals.

Tirzepatide adds a second hormone, GIP, which seems to boost the appetite effect and may explain its larger weight loss.

The surprising extra benefits

Researchers increasingly see these as metabolic medicines, not just weight-loss drugs:

  • Heart: in the SELECT trial of over 17,000 people with heart disease and excess weight, semaglutide cut heart attack, stroke and heart-related death by 20%. The benefit appeared regardless of how much weight people lost (NBC).
  • Kidneys: semaglutide is approved to slow kidney decline in people with type 2 diabetes and chronic kidney disease (AARP).
  • Liver: Wegovy is approved in the US to treat MASH, a serious form of fatty liver disease (NBC Palm Springs).
  • Sleep apnoea: tirzepatide is approved in the US to treat obstructive sleep apnoea in adults with obesity.
  • Blood pressure, cholesterol and joints: most trials show improvements, and less knee pain in people with osteoarthritis.

Researchers are also studying effects on alcohol cravings and brain health, but that evidence is still early.

Understanding “older” weight-loss medicines

Older medicines produce more modest weight loss, usually 3–10%, but they are cheaper and can still suit people who cannot take, afford or tolerate a GLP-1.

  • Orlistat (Xenical, Alli). Blocks fat absorption in the gut. It is the only one sold over the counter in the UK. Side effects are oily stools, urgency and wind, especially after fatty meals. Take a multivitamin at bedtime, as it reduces absorption of vitamins A, D, E and K.
  • Naltrexone-bupropion (Mysimba). Combines an addiction medicine and an antidepressant to reduce cravings. It can raise blood pressure and is unsuitable for people with seizures, uncontrolled high blood pressure or those using opioid painkillers. It carries a warning about mood changes.
  • Phentermine and phentermine-topiramate (Qsymia). A stimulant-type appetite suppressant, used mainly in the US and not licensed for weight loss in the UK. It can raise heart rate and disturb sleep, and topiramate can harm an unborn baby.
  • Liraglutide (Saxenda). The first GLP-1 approved for weight loss. It is a daily injection with smaller results than the weekly drugs, and cheaper generic versions are now appearing.

A practical rule many doctors use: if you have not lost at least 5% of your body weight after 3 months at the full dose, the medicine is unlikely to work for you and should be reviewed.

Genetic obesity: which drug is recommended?

For rare forms of obesity caused by a faulty gene in the brain’s appetite pathway, the recommended medicine is setmelanotide (Imcivree), a daily injection.

These conditions break the melanocortin-4 (MC4) pathway, the brain’s main “I’m full” switch. People affected typically have extreme, constant hunger and severe obesity from early childhood. Setmelanotide switches that pathway back on.

It is approved for obesity caused by:

  • POMC, PCSK1 or LEPR deficiency, confirmed by genetic testing, from age 2.
  • Bardet-Biedl syndrome (BBS), a rare inherited condition, from age 2.
  • Acquired hypothalamic obesity, caused by damage to the brain’s hunger centre (for example after a brain tumour), from age 4. The US approved this use in March 2026 and EU regulators backed it the same month (FDA label; EMA).

Setmelanotide does not work for common obesity, which is shaped by many genes plus environment. If severe obesity and relentless hunger began in early childhood, ask your doctor about referral to a specialist for genetic testing. A common side effect is skin darkening.

Common side effects and how to manage them

Most people get some stomach side effects, usually mild and mostly in the first weeks or after a dose increase. In the Wegovy pill trial, 74% had gut symptoms versus 42% on placebo, but only about 7% stopped because of side effects (Indian Pharma Post).

Side effect What helps
Nausea Eat small, slow meals; stop at the first sign of fullness; avoid greasy, fried or very sweet food; try ginger or plain crackers
Vomiting or diarrhoea Sip fluids through the day; use oral rehydration salts if it lasts; call your prescriber if you cannot keep fluids down
Constipation Drink 1.5–2 litres of water a day, build up fibre gradually, keep moving; ask a pharmacist about a gentle laxative
Heartburn or burping Avoid lying down within 3 hours of eating; cut back on fizzy drinks, alcohol and large evening meals
Tiredness or dizziness Usually from eating too little; make sure you still eat regular meals with enough protein and fluid
Hair thinning Usually temporary and linked to rapid weight loss; adequate protein, iron and zinc intake helps
Muscle loss Prioritise protein and strength training (see the long-term success section)

The golden rule is start low, go slow. Doses are raised step by step every 4 weeks. If side effects are hard to handle, your prescriber can hold you at a lower dose for longer rather than pushing up.

Rare but serious side effects: when to seek urgent help

Serious problems are uncommon, but you should know the warning signs and act fast. Seek urgent medical help (call 999 or 112, or go to A&E) for:

  • Pancreatitis: severe, constant tummy pain that may spread to your back, with or without vomiting. UK regulators have received hundreds of reports, some fatal, and are studying whether genes affect risk (Border Telegraph).
  • Gallbladder problems: pain in the upper right tummy, fever, or yellowing skin or eyes. Rapid weight loss raises the risk of gallstones.
  • Bowel blockage: severe bloating, cramping pain and being unable to pass wind or stools.
  • Severe dehydration: dizziness, very little urine or confusion after repeated vomiting or diarrhoea. This can damage the kidneys.
  • Sudden loss of vision: EU regulators class NAION, a stroke of the optic nerve, as a very rare semaglutide side effect affecting up to 1 in 10,000 users (EMA).
  • Severe allergic reaction: swelling of the face or throat, difficulty breathing or a widespread rash.

See your doctor promptly (not an emergency) for low mood or thoughts of self-harm, a lump or swelling in the neck, or signs of low blood sugar if you also take insulin or a sulfonylurea.

Before any operation or sedation, tell the team you take a GLP-1. Slower stomach emptying can raise the risk of food entering the lungs under anaesthetic.

In the UK, report suspected side effects or fake products to the MHRA Yellow Card scheme.

Who shouldn’t take GLP-1 drugs

GLP-1 drugs are not suitable for everyone, and some people must avoid them completely.

Do not take them if you:

  • Are pregnant, trying to conceive or breastfeeding. UK guidance says to use effective contraception, and to keep using it for up to 2 months after stopping before trying for a baby (Nowpatient summary of MHRA guidance).
  • Have a personal or family history of medullary thyroid cancer or MEN2 syndrome (a US label warning based on animal studies).
  • Have had a serious allergic reaction to the drug.

Use only with careful medical supervision if you have:

  • A history of pancreatitis or gallbladder disease.
  • Severe stomach or bowel conditions, such as gastroparesis or inflammatory bowel disease.
  • Diabetic eye disease (retinopathy), as rapid blood-sugar improvement can briefly worsen it.
  • Kidney problems, because dehydration from vomiting can make them worse.
  • A current or past eating disorder.
  • Type 1 diabetes, or you take insulin or sulfonylureas (higher risk of low blood sugar).

Contraception note: tirzepatide (Mounjaro) may make the contraceptive pill less effective in people who are overweight. A barrier or non-oral method is advised for 4 weeks after starting and after each dose increase (Pulse).

Counterfeit and compounded GLP-1s: what to know

The only safe GLP-1 is a licensed, branded product prescribed after a proper consultation and dispensed by a registered pharmacy. Fakes are a real and growing problem.

  • In 2025 the UK regulator seized more than 5,000 illegal GLP-1 products and shut down over 1,500 websites and social media accounts selling illegal medicines (Pharmaceutical Journal).
  • A single raid in Northampton found over 2,000 unlicensed pens, including retatrutide, an experimental drug not approved anywhere (Pharmaceutical Technology).
  • In the US, counterfeit Ozempic pens have reached the legitimate supply chain, and illegal products may contain too much, too little or none of the drug (SavingAdvice).

Red flags for fakes

  • Sold without a prescription or a real medical consultation
  • Sold by beauty salons, gyms, social media accounts or messaging apps
  • Prices far below the normal cost
  • Unbranded “semaglutide” or “tirzepatide” vials, or powders you mix yourself
  • Spelling mistakes, poor print, missing leaflet or broken seals
  • Pen looks, clicks or feels different from previous pens
  • Products labelled “research use only” or “not for human consumption”

In the UK, check an online pharmacy is listed on the General Pharmaceutical Council register. If something seems wrong, do not use it and report it via the Yellow Card scheme.

What about compounded versions?

Compounded drugs are custom-made copies mixed by pharmacies. They became widespread in the US during GLP-1 shortages, but they are not approved generics and do not go through regulators’ safety and quality review. The US FDA has received hundreds of adverse-event reports linked to compounded semaglutide and tirzepatide, often from dosing errors with vials and syringes (JumpstartMD). Now that shortages have ended, the FDA has moved to restrict mass compounding.

In the UK and EU, compounded GLP-1s are not a legal route for weight loss. If you are offered one, treat it as a warning sign.

GLP-1 drugs or weight-loss surgery?

Surgery still produces the largest and most lasting weight loss, while GLP-1s avoid an operation but usually need to be taken long term. In a real-world US study of over 50,000 people with a BMI of 35+, surgery patients lost 24% of body weight after 2 years versus 4.7% for those prescribed a GLP-1 (ASMBS). The gap was partly because many people stopped their medication; those who kept taking it did much better.

GLP-1 medicines Weight-loss surgery (sleeve or bypass)
Typical weight loss 10–20% in trials; often less in real life About 22–28%, sustained for years
How long Usually ongoing; weight tends to return if stopped One-off operation, lifelong follow-up
Risks Mostly stomach side effects; rare pancreatitis, gallstones Surgical risks, vitamin and mineral deficiencies, sometimes reflux or further surgery
Reversibility Stop at any time Largely permanent
Cost Ongoing monthly cost Large one-off cost (or NHS waiting list)
Best suited to BMI 30+ (or 27+ with conditions), people wanting to avoid surgery Usually BMI 40+, or 35+ with serious conditions such as type 2 diabetes

What to talk over with your doctor: how much weight you need to lose for your health, whether you would accept long-term medication, your surgical risk, and what is funded locally.

Increasingly it is not either/or. Some people use a GLP-1 to lose weight before surgery to make it safer, and others use one afterwards if weight starts to return.

A word on stopping. When people stop a GLP-1 suddenly, much of the weight comes back. In the STEP 1 extension, people regained about two-thirds of their lost weight within a year of stopping semaglutide (Diabetes, Obesity and Metabolism). This is biology, not a lack of willpower, so plan any change of dose with your prescriber.

Practical advice for long-term weight management

Medicine shrinks your appetite, but what you eat with that smaller appetite decides how healthy your weight loss is. A 2025 joint advisory from four US obesity and nutrition societies warns that GLP-1 users risk nutrient shortfalls and muscle and bone loss, and that up to two-thirds stop treatment within a year (PMC).

Habits that make results last

1. Protein first. Start each meal with protein (eggs, fish, chicken, Greek yoghurt, tofu, beans). Experts often suggest around 1.2 g per kg of body weight a day; a dietitian can set your personal target.

2. Lift something. Do strength training two to three times a week to protect muscle and bone. Walking alone is not enough.

3. Make every bite count. With smaller portions, choose vegetables, fruit, whole grains and healthy fats over ultra-processed snacks.

4. Fibre and fluids. Build up fibre slowly and drink plenty of water to prevent constipation.

5. Go easy on alcohol. It worsens nausea and adds empty calories.

6. Sleep and stress. Poor sleep and chronic stress both drive hunger hormones.

7. Track, don’t obsess. Weigh yourself weekly and check waist size monthly. Agree an “action point” with your prescriber, such as regaining 3 kg.

8. Plan the long game. Treat obesity like high blood pressure: a long-term condition. Discuss maintenance doses rather than stopping abruptly.

Where food supplements fit

Supplements cannot replace or mimic prescription GLP-1s. Be wary of products marketed as “nature’s Ozempic”; no supplement has been shown to match these medicines. But targeted supplements can help fill gaps when you are eating less:

  • A daily multivitamin and mineral helps cover shortfalls from smaller portions.
  • Vitamin D: UK health advice is that everyone consider 10 micrograms a day in autumn and winter.
  • Protein powders or shakes make it easier to hit protein targets when appetite is low.
  • Fibre supplements such as psyllium are one way to add fibre when portions are small; take them away from other medicines.
  • Creatine: daily creatine consumption can enhance the effect of resistance training on muscle strength in adults over the age of 55.
  • Electrolytes: after bouts of vomiting or diarrhoea, oral rehydration salts from a pharmacy replace lost fluid and salts.

Always tell your doctor or pharmacist what supplements you take. If you use the Wegovy pill, take it alone with a small sip of water on an empty stomach and wait 30 minutes before food, drinks, other medicines or supplements, or it may not be absorbed properly.

The bottom line

GLP-1 medicines are the biggest advance in obesity care in decades, with benefits for the heart, kidneys and liver as well as weight. They work best for people who meet the BMI criteria, take them under proper medical supervision, and pair them with good nutrition and strength training. They are not right for everyone, they carry real if uncommon risks, and the weight often returns if they are stopped without a plan.

If you think you might benefit, take this article to your GP or a registered online pharmacy and ask: Do I qualify? Which option suits my health? What will it cost, and what is the plan for the long term?

Swiss BioEnergetics perspective: no supplement replaces or mimics a prescription GLP-1 medicine. The medicine, enough protein and regular strength training do the work described above; food supplements can only sit alongside a well-planned diet while portions are smaller. Two of the nutrients this article mentions are in our range:

Vegan Vitamin D3 1000 IU
25 micrograms of algae-derived D3 per tablet. Vitamin D contributes to the maintenance of normal bones and normal muscle function, and the NHS suggests everyone consider 10 micrograms a day through autumn and winter.

Creatine Monohydrate Powder 500g
Pure creatine monohydrate, 5 g per scoop, 100 servings. Creatine increases physical performance in successive bursts of short-term, high intensity exercise; the beneficial effect is obtained with a daily intake of 3 g — a natural partner to the two or three strength sessions a week recommended above.

Whatever you take, tell your prescriber or pharmacist about it. If you use the Wegovy pill, take it on its own with a small sip of water on an empty stomach, and wait 30 minutes before any food, drink, other medicines or supplements.

This article is for general information only and does not replace advice from your doctor, pharmacist or dietitian. Never start, stop or change a prescription medicine without medical guidance. Food supplements should not be used as a substitute for a varied, balanced diet and a healthy lifestyle.

Sources

Back to blog